← All candidates
Eight insider buys in the last year — $434.50M in all.
23 filings on record.
PBLSParabilis Medicines, Inc.
NasdaqGS · Healthcare · $5.16B
$41.73
+2.08% · Sep 18
Eight insider buys in the last year — $434.50M in all.
Nothing in the last fortnight.
Price · 1Y · daily● 8 buys◆ 1 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 2 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$5.16B
Float
82.1M
67% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
34831.4
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
10% owner
Ra Capital Management, L.p.
Bought $394.57M on Jun 11 — 19,728,353 sh @ $20.00, held indirect, 75% of their stake.
4 of 8 positions beat the S&P
10% owner
Levy Guy
Bought $7.50M on Jun 11 — 375,000 sh @ $20.00, held indirect, 37% of their stake.
No completed positions to measure
Director
Sebulsky Alan
Bought $250.0K on Jun 11 — 12,500 sh @ $20.00, held indirect, 100% of their stake.
No completed positions to measure
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
18 more transactions on Pro →Context
Wall St
$41.75 avg target
+0.0% vs today · 4 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
0 of 1 quarters beat
Q2 '26−$2.12 act−$1.88
The file stays open
23 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice